Recently, two clinical trials have demonstrated the efficacy of nerandomilast (a specific PDE-4B inhibitor) in idiopathic pulmonary fibrosis (IPF) [16] and progressive pulmonary fibrosis (PPF) [17]. Here, PDE4B is linked to idiopathic pulmonary fibrosis.